Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112

Biochemical Pharmacology

Volumn 80, Issue 6, 2010, Pages 801-810

  Chen, Liwei ^a   Pernazza, Daniele ^a   Scott, Latanya M ^a   Lawrence, Harshani R ^a   Ren, Yuan ^a   Luo, Yunting ^a   Wu, Xin ^a   Sung, Shen Shu ^a   Guida, Wayne C ^a   Sebti, Said M ^a,b   Lawrence, Nicholas J ^a,b   Wu, Jie ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Erk1 2; Inhibitor; Protein tyrosine phosphatase; PTPN11; Shp2

Indexed keywords

[3 (2 (5 (N (4 FLUOROBENZYL)SULFAMOYL) 2 OXOINDOLIN 3 YLIDENE)HYDRAZINYL)BENZOIC ACID METHYL ESTER]; [3 (2 (5 (N (4 FLUOROBENZYL)SULFAMOYL) 2 OXOINDOLIN 3 YLIDENE)HYDRAZINYL)BENZOIC ACID]; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; ESTER DERIVATIVE; GAMMA INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NSC 117199; PAXILLIN; PROTEIN BCL XL; PROTEIN P21; PROTEIN TYROSINE PHOSPHATASE SHP 2; SPI 112; STAT1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL SURVIVAL; CONFOCAL LASER MICROSCOPY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE; HUMAN; HUMAN CELL; HYDROLYSIS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SURFACE PLASMON RESONANCE;

BINDING, COMPETITIVE; CELL LINE, TRANSFORMED; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HT29 CELLS; HUMANS; INDOLES; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; SULFONAMIDES; SULFONIC ACIDS;

EID: 77954761479     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.05.019     Document Type: Article

References (49)

1. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
2. Deininger M., Buchdunger E., Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640-2653.
3. Mulloy R., Ferrand A., Kim Y., Sordella R., Bell D.W., Haber D.A., et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 2007, 67:2325-2330.
4. Bentires-Alj M., Paez J.G., David F.S., Keilhack H., Halmos B., Naoki K., et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 2004, 64:8816-8820.
5. Boutros R., Lobjois V., Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets?. Nat Rev Cancer 2007, 7:495-507.
6. Stephens B.J., Han H., Gokhale V., Van Hoff D.D. PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther 2005, 4:1653-1661.
7. Tonks N.K., Muthuswamy S.K. A brake becomes an accelerator: PTP1B--a new therapeutic target for breast cancer. Cancer Cell 2007, 11:214-216.
8. Jiang Z.X., Zhang Z.Y. Targeting PTPs with small molecule inhibitors in cancer treatment. Cancer Metastasis Rev 2008, 27:263-272.
9. Lawrence H.R., Pireddu R., Chen L., Luo Y., Sung S.S., Szymanski A.M., et al. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J Med Chem 2008, 51:4948-4956.
10. Hellmuth K., Grosskopf S., Lum C.T., Wurtele M., Roder N., von Kries J.P., et al. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc Natl Acad Sci U S A 2008, 105:7275-7280.
11. Geronikaki A., Eleftheriou P., Vicini P., Alam I., Dixit A., Saxena A.K. 2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action. J Med Chem 2008, 51:5221-5228.
12. Johnston P.A., Foster C.A., Tierno M.B., Shun T.Y., Shinde S.N., Paquette W.D., et al. Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. Assay Drug Dev Technol 2009, 7:250-265.
13. Scott L.M., Lawrence H.R., Sebti S.M., Lawrence N.J., Wu J. Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr Pharm Des 2010, 16:1843-1862.
14. Neel B.G., Gu H., Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 2003, 28:284-293.
15. Cunnick J.M., Mei L., Doupnik C.A., Wu J. Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2. J Biol Chem 2001, 276:24380-24387.
16. Ren Y., Meng S., Mei L., Zhao Z.J., Jove R., Wu J. Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. J Biol Chem 2004, 279:8497-8505.
17. Zhan Y., Counelis G.J., O'Rourke D.M. The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells. Exp Cell Res 2009, 315:2343-2357.
18. Zhou X., Agazie Y.M. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation. J Biol Chem 2009, 284:12226-12234.
19. Tartaglia M., Gelb B.D. Germ-line and somatic PTPN11 mutations in human disease. Eur J Med Genet 2005, 48:81-96.
20. Kratz C.P., Niemeyer C.M., Castleberry R.P., Cetin M., Bergstrasser E., Emanuel P.D., et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 2005, 106:2183-2185.
21. Ren Y., Chen Z., Chen L., Woods N.T., Reuther G.W., Cheng J.Q., et al. Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL. J Biol Chem 2007, 282:36463-36473.
22. Keilhack H., David F.S., McGregor M., Cantley L.C., Neel B.G. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem 2005, 280:30984-30993.
23. Chan G., Kalaitzidis D., Usenko T., Kutok J.L., Yang W., Mohi M.G., et al. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood 2009, 113:4414-4424.
24. Wu T.R., Hong Y.K., Wang X.D., Ling M.Y., Dragoi A.M., Chung A.S., et al. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J Biol Chem 2002, 277:47572-47580.
25. You M., Yu D.H., Feng G.S. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol 1999, 19:2416-2424.
26. Baron M., Davignon J.L. Inhibition of IFN-gamma-induced STAT1 tyrosine phosphorylation by human CMV is mediated by SHP2. J Immunol 2008, 181:5530-5536.
27. Bialy L., Waldmann H. Inhibitors of protein tyrosine phosphatases: next-generation drugs?. Angew Chem Int Ed Engl 2005, 44:3814-3839.
28. Chen L., Sung S.S., Yip M.L., Lawrence H.R., Ren Y., Guida W.C., et al. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol Pharmacol 2006, 70:562-570.
29. Zhao X.T., Qian Y.K., Chan A.W., Madhavan R., Peng H.B. Regulation of ACh receptor clustering by the tyrosine phosphatase Shp2. Dev Neurobiol 2007, 67:1789-1801.
30. Fuchikawa T., Nakamura F., Fukuda N., Takei K., Goshima Y. Protein tyrosine phosphatase SHP2 is involved in Semaphorin 4D-induced axon repulsion. Biochem Biophys Res Commun 2009, 385:6-10.
31. Boutselis I.G., Yu X., Zhang Z.Y., Borch R.F. Synthesis and cell-based activity of a potent and selective protein tyrosine phosphatase 1B inhibitor prodrug. J Med Chem 2007, 50:856-864.
32. Qian Y.K., Chan A.W., Madhavan R., Peng H.B. The function of Shp2 tyrosine phosphatase in the dispersal of acetylcholine receptor clusters. BMC Neurosci 2008, 9:70.
33. Chatterjee P.K., Al-Abed Y., Sherry B., Metz C.N. Cholinergic agonists regulate JAK2/STAT3 signaling to suppress endothelial cell activation. Am J Physiol Cell Physiol 2009, 297:C1294-C1306.
34. Nören-Müller A., Reis-Correa I., Prinz H., Rosenbaum C., Saxena K., Schwalbe H.J., et al. Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proc Natl Acad Sci U S A 2006, 103:10606-10611.
35. Wu D., Pang Y., Ke Y., Yu J., He Z., Tautz L., et al. A conserved mechanism for control of human and mouse embryonic stem cell pluripotency and differentiation by shp2 tyrosine phosphatase. PLoS One 2009, 4:e4914.
36. Zhang X., He Y., Liu S., Yu Z., Jiang Z.X., Yang Z., et al. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J Med Chem 2010, 53:2482-2493.
37. Hof P., Pluskey S., Dhe-Paganon S., Eck M.J., Shoelson S.E. Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998, 92:441-450.
38. Muller K.M., Arndt K.M., Bauer K., Pluckthun A. Tandem immobilized metal-ion affinity chromatography/immunoaffinity purification of His-tagged proteins-evaluation of two anti-His-tag monoclonal antibodies. Anal Biochem 1998, 259:54-61.
39. Nordin H., Jungnelius M., Karlsson R., Karlsson O.P. Kinetic studies of small molecule interactions with protein kinases using biosensor technology. Anal Biochem 2005, 340:359-368.
40. Joss L., Morton T.A., Doyle M.L., Myszka D.G. Interpreting kinetic rate constants from optical biosensor data recorded on a decaying surface. Anal Biochem 1998, 261:203-210.
41. Greco W.R., Faessel H., Levasseur L. The search for cytotoxic synergy between anticancer agents: a case of Dorothy and the ruby slippers?. J Natl Cancer Inst 1996, 88:699-700.
42. Ribble D., Goldstein N.B., Norris D.A., Shellman Y.G. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 2005, 5:12.
43. Streiber M., Picard F., Scherer C., Seidel S.B., Hartmann R.W. Methyl esters of N-(dicyclohexyl)acetyl-piperidine-4-(benzylidene-4-carboxylic acids) as drugs and prodrugs: a new strategy for dual inhibition of 5 alpha-reductase type 1 and type 2. J Pharm Sci 2005, 94:473-480.
44. Manne V., Yan N., Carboni J.M., Tuomari A.V., Ricca C.S., Brown J.G., et al. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene 1995, 10:1763-1779.
45. Manes S., Mira E., Gomez-Mouton C., Zhao Z.J., Lacalle R.A., Martinez A.C. Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility. Mol Cell Biol 1999, 19:3125-3135.
46. Vadlamudi R.K., Adam L., Nguyen D., Santos M., Kumar R. Differential regulation of components of the focal adhesion complex by heregulin: role of phosphatase SHP-2. J Cell Physiol 2002, 190:189-199.
47. Cunnick J.M., Meng S., Ren Y., Desponts C., Wang H.G., Djeu J.Y., et al. Regulation of the mitogen-activated protein kinase signaling pathway by SHP2. J Biol Chem 2002, 277:9498-9504.
48. Chin Y.E., Kitagawa M., Su W.C., You Z.H., Iwamoto Y., Fu X.Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996, 272:719-722.
49. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.